Anavex Life Sciences Corp.   Report issue

For profit Phase 1 Phase 3
Founded: New York NY United States (2004)

Organization Overview

First Clinical Trial
2014
NCT02244541
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Anavex Australia Pty Ltd. | Anavex Germany GmbH | Anavex Life Sciences Corp.

Active Ingredients

Drugs in Phase 3 Trials (1)

blarcamesine (9 trials)

Drugs in Phase 1 Trials (2)

anavex3-71 (1 trial)

ketamine (ketalar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Dementia (Phase 2)

Parkinson Disease (Phase 2)

Rett Syndrome (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 3